Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity

References

• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691–709.
   PubMed Web of Science ®Google Scholar
• Faderl S, Garcia‐Manero G, Thomas DA, Kantarjian HM. Philadelphia chromosome‐positive acute lymphoblastic leukemia–current concepts and future perspectives. Rev Clin Exp Hematol. 2002;6(2):142–160.
   PubMedGoogle Scholar
• Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1(7):493–502.
   PubMed Web of Science ®Google Scholar
• Pandrala M, Bruyneel AAN, Hnatiuk AP, Mercola M, Malhotra SV. Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety. J Med Chem. 2022;65(16):10898–10919.
   PubMedGoogle Scholar
• Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaecla J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28–37.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Eide CA, Deininger MWN. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110(7):2242–2249.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res. 2008;14(14):4392–4399.
   PubMed Web of Science ®Google Scholar
• Le Coutre P, Ottmann OG, Giles F, Kim D-W, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008;111(4):1834–1839.
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399–401.
   PubMed Web of Science ®Google Scholar
• Boschelli DH, Ye F, Wang YD, Dutia M, Johnson SL, Wu B, Miller K, Powell DW, Yaczko D, Young M, et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem. 2001;44(2001):3965–3977.
   PubMedGoogle Scholar
• Vener C, Banzi R, Ambrogi F, Ferrero A, Saglio G, Pravettoni G, et al. First-line imatinib vs second-and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. Blood Adv . 2020;4(12):2723–2735.
   PubMed Web of Science ®Google Scholar
• FDA. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ponatinib-marketed-iclusig-informaton
   Google Scholar
• Huang WS, Metcalf CA, Sundaramoorthi R, Wang YH, Zou D, Thomas RM, et al. Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I gatekeeper mutant. J Med Chem. 2010;53(12):4701–4719.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Shakespeare WC, Zhu XT, Eide CA, Rivera VM, Wang F, et al. AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401–412.
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Deininger M. Tyrosine kinase inhibitor–associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33(35):4210–4218.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Li ZR, Qin YZ, Li WM, Xu N, Liu BC, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2022;15(1):1–17.
   PubMed Web of Science ®Google Scholar
• Liu XS, Wang BL, Chen C, Jiang ZR, Hu C, Wu H, et al. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia. Eur J Med Chem. 2018;160:61–81.
   PubMed Web of Science ®Google Scholar
• Hong S, Kim J, Yun SM, Lee H, Park Y, Hong SS, et al. Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-abelson kinase including the T315I mutant. J Med Chem. 2013;56(9):3531–3545.
   PubMed Web of Science ®Google Scholar
• El-Damasy AK, Cho NC, Kang SB, Pae AN, Keum G. ABL kinase inhibitory and antiproliferative activity of novel picolinamide based benzothiazoles. Bioorg Med Chem Lett. 2015;25(10):2162–2168.
   PubMed Web of Science ®Google Scholar
• El-Damasy AK, Cho NC, Nam G, Pae AN, Keum G. Discovery of a nanomolar multikinase inhibitor (KST016366): A new benzothiazole derivative with remarkable broad-spectrum antiproliferative activity. ChemMedChem. 2016;11(15):1587–1595.
   PubMed Web of Science ®Google Scholar
• Lee JH, El-Damasy AK, Seo SH, Gadhe CG, Pae AN, Jeong N, et al. Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study. Bioorg Med Chem. 2018;26(21):5596–5611.
   PubMed Web of Science ®Google Scholar
• Fang ZH, Han B, Jung KH, Lee JH, El-Damasy AK, Gadhe CG, et al. A novel tropomyosin-related kinase A inhibitor, KK5101 to treat pancreatic cancer. Cancer Lett. 2018;426:25–36.
   PubMed Web of Science ®Google Scholar
• El-Damasy AK, Haque MM, Park JW, Shin SC, Lee JS, Kim EE, et al. 2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAF(V600E)/C-RAF kinase inhibitory effects: Design, synthesis, in vitro cell-based and oncogenic kinase assessments. Eur J Med Chem. 2020;208:112756.
   PubMed Web of Science ®Google Scholar
• El-Damasy AK, Jin H, Seo SH, Bang EK, Keum G. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity. Eur J Med Chem. 2020;207:112710.
   PubMed Web of Science ®Google Scholar
• El-Damasy AK, Seo SH, Cho NC, Pae AN, Kim EE, Keum G. Design and synthesis of new 2-anilinoquinolines bearing N-methylpicolinamide moiety as potential antiproliferative agents. Chem Biol Drug Des. 2017;89(1):98–113.
   PubMed Web of Science ®Google Scholar
• Reaction Biology Corporation. http://www.reactionbiology.com/webapps/site/Kinase_Assay_Protocol.aspx
   Google Scholar
• Vogel W. Discoidin domain receptors: structural relations and functional implications. Faseb J. 1999;13(9001):S77–S82.
   PubMedGoogle Scholar
• Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharm. 2008;599(1-3):44–53.
   PubMed Web of Science ®Google Scholar
• Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1(3):1112–1116.
   PubMed Web of Science ®Google Scholar
• https://dtp.cancer.gov/dtpstandard/dwindex/index.jsp
   Google Scholar
• Vlahovic G, Rabbani ZN, Herndon JE, Dewhirst MW, Vujaskovic Z. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Brit J Cancer. 2006;95(8):1013–1019.
   PubMed Web of Science ®Google Scholar
• Vlahovic G, Ponce AM, Rabbani Z, Salahuddin FK, Zgonjanin L, Spasojevic I, et al. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Brit J Cancer. 2007;97(6):735–740.
   PubMed Web of Science ®Google Scholar
• Mazzocca A, Napolitano A, Silletta M, Ceruso MS, Santini D, Tonini G, et al. New frontiers in the medical management of gastrointestinal stromal tumours. Ther Adv Med Oncol. 2019;11:1–13.
   Web of Science ®Google Scholar
• Shergalis A, Bankhead A, Luesakul U, Muangsin N, Neamati N. Current Challenges and Opportunities in Treating Glioblastoma. Pharmacol Rev. 2018;70(3):412–445.
   PubMed Web of Science ®Google Scholar
• Kim G, Ko YT. Small molecule tyrosine kinase inhibitors in glioblastoma. Arch Pharmacal Res. 2020;43(4):385–394.
   PubMed Web of Science ®Google Scholar
• Matei D, Emerson RE, Schilder J, Menning N, Baldridge LA, Johnson CS, et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis - A hoosier oncology group trial. Cancer. 2008;113(4):723–732.
   PubMed Web of Science ®Google Scholar
• Tokarski JS, Newitt JA, Chang CYJ, Cheng JD, Wittekind M, Kiefer SE, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006;66(11):5790–5797.
   PubMed Web of Science ®Google Scholar
• Zhou T, Parillon L, Li F, Wang Y, Keats J, Lamore S, Xu Q, Shakespeare W, Dalgarno D, Zhu X, et al. Crystal structure of the T315I mutant of Abl kinase. Chem Biol Drug Des. 2007;70(3):171–181.
   PubMed Web of Science ®Google Scholar
• http://www.swissadme.ch/index.php
   Google Scholar